Tiziana Life Sciences plc ("Tiziana" or the "Company") - Appointment of Director
February 05 2021 - 2:00AM
Tiziana Life Sciences plc (NASDAQ: TLSA / LSE: TILS) ("Tiziana" or
the "Company"), a biotechnology company focused on innovative
therapeutics for oncology, inflammation, and infectious diseases,
today announces the appointment of Dr. Thomas Adams, Ph.D. as an
executive director.
Dr. Adams will assume the position of Head of
Drug Development with immediate effect and his executive role will
be to manage and oversee all matters relating to the Company's
pre-clinical and clinical drug development programs and associated
intellectual property.
Dr. Thomas H. Adams (age:
78)
Dr. Adams holds a Ph.D. in Biochemistry from the
University of California, Riverside. The Board believes that Dr.
Adams’ executive leadership and the extensive healthcare expertise
he has developed makes Dr. Adams ideally qualified to serve as an
additional director of the Company.
Dr. Adams, has been a director of Cardiff
Oncology, Inc (NASDAQ: CRDF) ("Cardiff") since June 2018, serving
in the roles of Chief Executive Officer from June 2018 to May 2020,
as chairman of the board from April 2009 to December 2020 and as
Executive Chairman from May through December 2020.
At Cardiff, Dr. Adams led the development and
repurposing of onvansertib, a first-in-class, third-generation
Polo-like Kinase 1 (PLK1) inhibitor, in combination with
standard-of-care chemotherapy and targeted therapeutics, for the
potential treatment of KRAS-mutated metastatic colorectal cancer
(mCRC), metastatic castration-resistant prostate cancer and
relapsed or refractory acute myeloid leukemia.
He is currently a Director at Hepion
Pharmaceuticals, Inc. (NASDAQ: HEPA), where he has served since
2014. Previously, Dr. Adams served as Chairman of Clearbridge
BioPhotonics, Inc., an imaging solutions company, from 2013 to
2019, and as Director of Synergy Pharmaceuticals, Inc. from 2009 to
2019.
He served in several leadership roles at IRIS
International, including Director, Head of Personalized Medicine
and Chief Technology Officer, from 2005 until the company’s
acquisition by Danaher Corporation in 2012.
From 1998 to 2006, Dr. Adams was Chairman and
Chief Executive Officer of Leucadia Technologies, a privately held
biotechnology company which was acquired by IRIS International,
Inc. in 2006.
Dr. Adams founded Genta, Inc. in 1989 and served
as its Chief Executive Officer until 1997. He also founded
Gen-Probe, Inc. in 1984 and served as Chairman and Chief Executive
Officer until its acquisition by Chugai Biopharmaceuticals, Inc. in
1989.
Dr. Adams stated, “I am excited to join the team
at Tiziana to focus on developing Foralumab and Milciclib. These
new targeted therapies promise to deliver relief to patients
suffering from cancer, inflammatory and infectious disease. My
experience in precision medicine utilizing targeted therapies with
precision diagnostics should accelerate the delivery of these
important therapeutics.”
Gabriele Cerrone, Chairman of Tiziana, said, "We
are delighted to welcome Dr. Adams to the Board and consider that
his proven track record in the field of cancer could add
significant value to the development of the Company's Milciclib and
Foralumab oncology programs."
This announcement contains inside
information.
Pursuant to Listing Rule 9.6.13, in connection
with Dr. Adams' appointment, Dr. Adams was Executive Chairman of
Synergy Pharmaceuticals Inc. until October 2018. In December 2018
Synergy Pharmaceuticals Inc. (then listed on NASDAQ), filed for
Chapter 11 bankruptcy in the USA. The company currently remains in
the administration process. There are no other disclosures to make
pursuant to Listing Rule 9.6.13, in respect of Dr. Adams'
appointment.
About Tiziana Life Sciences
Tiziana Life Sciences plc is a UK biotechnology
company that focuses on the discovery and development of novel
molecules to treat human disease in oncology and immunology. In
addition to Milciclib, the Company is also developing Foralumab for
liver diseases. Foralumab is the only fully human anti-CD3
monoclonal antibody in clinical development in the world. This
Phase 2 compound has potential application in a wide range of
autoimmune and inflammatory diseases, such as nonalcoholic
steatohepatitis (NASH), ulcerative colitis, multiple sclerosis,
type-1 diabetes (T1D), Crohn's disease, psoriasis and rheumatoid
arthritis, where modulation of a T-cell response is desirable. The
company is accelerating development of anti-Interleukin 6 receptor
(IL6R) mAb, a fully human monoclonal antibody for treatment of
IL6-induced inflammation, especially for treatment of COVID-19
patients.
For further enquiries:United Kingdom
Investors:
Tiziana Life Sciences
plcGabriele Cerrone, Chairman and founder |
+44 (0)20 7495 2379 |
U.S. Investor Contact:RedChip Companies, Inc.Dave
Gentry407-491-4498dave@redchip.com
Hepion Pharmaceuticals (NASDAQ:HEPA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Hepion Pharmaceuticals (NASDAQ:HEPA)
Historical Stock Chart
From Apr 2023 to Apr 2024